Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia. This evidence concerns the gene PPARG and chronic myelogenous leukemia, BCR-ABL1 positive.